Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 58 Continued value growth in the Chinese long-acting insulin segment Chinese insulin market by segment Chinese total insulin value market shares Device penetration Modern insulin penetration Novo Nordisk bDKK Penetration Sanofi CAGR value¹: 14.7% 0.1 100% 70% 60% 0.1 - 80% Fast-acting 50% 0.1 0.0 Premix 60% 40% 30% 40% 20% 0.0 20% Long-acting 10% 0.0 Nov 2012 0% 0% Nov Nov 2017 2012 1 CAGR for 5-year period Note: IMS covers around 50% of the total Chinese market (hospital data) Source: IQVIA (formerly IMS) Rolling MAT Nov, 2017 value (DKK) figures changing diabetes® Eli Lilly Tonghua Dongbao - Gan & Lee Other -50% 17% 12% 11% 6% 4% Nov 2017 Note: Only selected competitors Source: IQVIA (formerly IMS) Rolling MAT Nov, 2017 value figures, numbers do not add up to 100% due to smaller insulin manufacturers not included novo nordisk

View entire presentation